Therapeutic Advances in Cardiovascular Disease

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Register here to gain access to SAGE's 500+ Journals Online

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Google Scholar
Right arrow Articles by Jimenez-Valero, S.
Right arrow Articles by López-Sendón, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Therapeutic Advances in Cardiovascular Disease, Vol. 2, No. 3, 137-146 (2008)
DOI: 10.1177/1753944708090573

Reviews

Review: Avoiding restenosis: is there a role for glucocorticoids in the drug-eluting stent era?

Santiago Jimenez-Valero

Cardiology Unit, Hospital La Paz, Avda. Castellana 261, CP 28046, Madrid, Spain, sjvcardio{at}yahoo.es

Raul Moreno

Cardiology Unit, Hospital La Paz, Avda. Castellana 261, CP 28046, Madrid, Spain

Angel Sanchez-Recalde

Cardiology Unit, Hospital La Paz, Avda. Castellana 261, CP 28046, Madrid, Spain

Guillermo Galeote

Cardiology Unit, Hospital La Paz, Avda. Castellana 261, CP 28046, Madrid, Spain

Luis Calvo

Cardiology Unit, Hospital La Paz, Avda. Castellana 261, CP 28046, Madrid, Spain

Ana Viana

Cardiology Unit, Hospital La Paz, Avda. Castellana 261, CP 28046, Madrid, Spain

Esteban Lopez de Sá

Cardiology Unit, Hospital La Paz, Avda. Castellana 261, CP 28046, Madrid, Spain

Jose López-Sendón

Cardiology Unit, Hospital La Paz, Avda. Castellana 261, CP 28046, Madrid, Spain

Restenosis is an important limitation of percutaneous coronary interventions (PCI). In-stent restenosis is mainly due to neointimal hyperplasia, a proliferative process modulated by inflammatory mechanisms. Numerous technical and pharmacological means have been tested to reduce restenosis rates, with frequently disappointing clinical results. Drug-eluting stents (DES) have demonstrated a high efficacy in reducing restenosis, but there are some associated problems that limit its generalized utilization. Glucocorticoids (GC), as potent anti-inflammatory agents, may exert beneficial effects on neointimal proliferation. Clinical studies with oral and intracoronary GC therapy have demonstrated reduction in restenosis rates in selected patients. Although further investigations are warranted, GC might have a potential role for restenosis prevention in selected cases.

Key Words: Glucocorticoids • stent • steroids • drug-eluting stent • restenosis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?